Jan 6Liked by Jessica Sacher, PhD

Hi Jessica

Fascinating article.

I'm delighted to discover your move to Australia is paying dividends. Clearly you have come a long way since we talked a couple of years ago.

We are already seeing some of our investments in non toxic infection control coming to profitable fruition.

Phage technology is high on our list of potential investments. However I'm still puzzling over the shape of commercial opportunities in phage technology. Any thoughts on that?

Best wishes



Expand full comment
Dec 20, 2022Liked by Jessica Sacher, PhD

Thank you so much for the opportunity to get a closer look into the phage.kitchen, Jessica. Good move to go to Australia! We are short of phage labs in Germany and Europe, our regulatory body imposed full genome sequencing under GMP standards, which stopped all activities immediately for being much too costly and time consuming. At least for compassionate cases, I therefore liked your statement on being less perfect in favour of rescuing people.

I got one question, still: How (and where) would you draw the line between regular treatment and (early enough) compassionate treatment eventually?

Thanks for advising. Have a nice Christmas leave! Warm regards - Barbara (Bonn/D)

Expand full comment
Dec 19, 2022Liked by Jessica Sacher, PhD

Yes! It will be excellent to pair antibiotic lvls with phage. We can talk soon when you are available to as I m cognizant that it is holiday season for many

Expand full comment
Dec 19, 2022Liked by Jessica Sacher, PhD

I love this! We are starting phage therapy in Singapore. I have thought about this before and I have no answers to them. We have braced ourselves to take the bull by its horns when it comes charging….And this journal is totally useful now to know what to expect ( before the bulls come charging!). My team and myself will love to visit Jessica’s lab next year if we can!

Andrea Kwa

Expand full comment

Thanks for reading, David, so nice to see you here - it’s been a while! (Time really has flown - feels like the other day). That’s awesome about the infection control companies -- really good to hear.

I agree that phage is tricky to commercialize. We are feeling out the idea of phage therapy as a clinical/diagnostics service / possibly even an insurance product for hospitals / health payers (ie. they pay for access for their patients to have phage sourcing, matching, production done, and administer their phages through compassionate use channels for patients in need - a growing number), rather than trying to develop the phages themselves as a collection of biologic drugs. Besides that, my colleague Ruby Lin has been writing about her thoughts on a bunch of different phage therapy commercialization opportunities at https://phageaustralia.org/blog, if you want to have a look. Would love to hear your take!

Expand full comment